Tango Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 140
- Market Cap
- $1.2B
- Website
- http://www.tangotx.com
- Introduction
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr....
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Tango Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT06065059
- Locations
- ๐บ๐ธ
New York University Langone Health, New York, New York, United States
๐บ๐ธMid Florida Cancer Centers, Orange City, Florida, United States
๐บ๐ธFlorida Cancer Specialists, Sarasota, Florida, United States
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Tango Therapeutics, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05887492
- Locations
- ๐บ๐ธ
NEXT Oncology Virginia, Fairfax, Virginia, United States
๐บ๐ธUCLA Hematology/Oncology, Santa Monica, California, United States
๐บ๐ธFlorida Cancer Specialists, Sarasota, Florida, United States
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Tango Therapeutics, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT05732831
- Locations
- ๐บ๐ธ
Next Oncology Virginia, Fairfax, Virginia, United States
๐บ๐ธStanford University, Palo Alto, California, United States
๐บ๐ธGrand Valley Oncology, Grand Junction, Colorado, United States
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Tango Therapeutics, Inc.
- Target Recruit Count
- 192
- Registration Number
- NCT05275478
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
๐บ๐ธUniversity of California Los Angeles, Los Angeles, California, United States
๐บ๐ธUniversity of California San Francisco, San Francisco, California, United States